US EditionBioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - BioMarin Pharmaceutical (NASDAQ:BMRN)
MARIN COUNTY, CALIFORNIA, AUG 5 – BioMarin reported $825 million in Q2 revenue, up 16%, driven by 20% VOXZOGO sales growth and advanced its clinical pipeline including the acquisition of Inozyme Pharma.
- Today, BioMarin Pharmaceutical Inc. raised its full-year guidance after reporting second quarter 2025 results with $825 million in revenues and $1.44 in Non-GAAP Diluted EPS .
- With VOXZOGO revenue increasing 20% Y/Y, driven by new patient initiations worldwide, BioMarin reports total revenues of $825 million for Q2 2025.
- Non-GAAP Income increased by $93 million to $282 million, a 49% gain, reflecting BioMarin's profit growth in Q2 2025.
- The acquisition of Inozyme on July 1 added BMN 401 for ENPP1 Deficiency, and BMN 333 met targeted exposure levels in the healthy volunteer study.
- The guidance also accounts for enacted tariffs and assumes new tariffs will have limited impact in 2025, with VOXZOGO's topline data expected in 1H'26 for hypochondroplasia, BioMarin said.
Insights by Ground AI
Does this summary seem wrong?
22 Articles
22 Articles
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth. Latest Ratings for BMRN DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Nov 2021Credit SuisseMaintainsOutperform Nov 2021Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for BMRN View the Latest Analyst Ratings
·New York, United States
Read Full Article
Coverage Details
Total News Sources22
Leaning Left1Leaning Right0Center10Last UpdatedBias Distribution91% Center
Bias Distribution
- 91% of the sources are Center
91% Center
C 91%
Factuality
To view factuality data please Upgrade to Premium
